Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03985293 · ClinicalTrials.gov registry record · Phase 2
A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 412
- Enrollment target
NCT03985293 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 412 participants.
The verdict
NCT03985293, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 412 participants
- Enrollment target
Study Summary
This multicenter, randomized, double-blind, placebo controlled, parallel group study is being conducted to provide data on efficacy, safety, tolerability and pharmacokinetics (PK) of multiple dose levels of PF-06882961 in adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and/or diet and exercise. In addition, the study is intended to enable selection of efficacious doses for future clinical development of PF-06882961.
Interventions
- DRUG Placebo
- DRUG PF-06882961
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 412 participants |
| Start Date | 2019-10-15 |
| Est. Completion | 2021-07-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03985293
The ClinicalTrials.gov registry entry for NCT03985293 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 412 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03985293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03985293 about?
NCT03985293 is a clinical study titled "A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus". This multicenter, randomized, double-blind, placebo controlled, parallel group study is being conducted to provide data on efficacy, safety, tolerability and pharmacokinetics (PK) of multiple dose levels of PF-06882961 in adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metform...
What is the current status of trial NCT03985293?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 412 participants. The study started on 2019-10-15. Estimated completion is 2021-07-07.
What interventions are being tested in trial NCT03985293?
The interventions under investigation include: Placebo (DRUG), PF-06882961 (DRUG).
Who is sponsoring clinical trial NCT03985293?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.